Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation
TORONTO, ON / ACCESSWIRE / December 15, 2020 / Ripple Therapeutics Corporation ( Ripple or the Company ), a clinical stage, ophthalmology-focused developer of novel therapeutics, announced today the signing of an exclusive Licensing Agreement for the rights to their lead product, IBE-814, for North America and Europe with Théa Open Innovation ( TOI ) a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. In addition to the Licensing Agreement, Ripple announced that TOI is leading their Series A Financing.
Ripple s Epidel
® technology platform is founded on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. The proprietary prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal
Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Thea Open Innovation albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation
TORONTO, ON / ACCESSWIRE / December 15, 2020 / Ripple Therapeutics Corporation ( Ripple or the Company ), a clinical stage, ophthalmology-focused developer of novel therapeutics, announced today the signing of an exclusive Licensing Agreement for the rights to their lead product, IBE-814, for North America and Europe with Théa Open Innovation ( TOI ) a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. In addition to the Licensing Agreement, Ripple announced that TOI is leading their Series A Financing.
Ripple s Epidel
® technology platform is founded on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. The proprietary prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal
Permission required for outside use. Contact: TheWordWenches@gmail.com
Exercising Your Demons!
Andrea here, thinking today on how we’re all spending a lot more time at home . . . and some of the ramifications involved in sheltering-in-place, especially as here in the northern hemisphere we’re fast approaching the heart of winter . . . which make it even more inviting to curl up in front of the fire with good book and a cup of cocoa.
And maybe cookies. Or chocolate . . .
Pandemic baking is one of those ramifications. NOT that I’m guilty of overindulging in sweets. (
Pssst, this Andrea’s editorial assistant, and just so you know, a batch of chocolate-chip blondies just came out of the oven. But you didn’t hear that from me!) Okay, well, maybe I do have a few extra “comfort” treats. The Wenches have been sharing recipes with each other, and so many of them look SO good. (Anne and Christina have been especially bad at leading us astray!) But after all, it wouldn’t be